Brooks C. Wingo

Dr. Brooks C. Wingo

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2014 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
BWBrooks C. Wingo
Brooks C. Wingo
TCT. L. Carson
T. L. Carson
JAJ. Ard
J. Ard

1 December 2018 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
BWBrooks C. Wingo
Brooks C. Wingo
VBValene Garr Barry
Valene Garr Barry
AEAmy C. Ellis
Amy C. Ellis
BGBarbara Gower
Barbara Gower

1 July 2013 in Journal of Nutrition Education and Behavior
Verified
Journal Article
Closed access
BWBrooks C. Wingo
Brooks C. Wingo
RDRenee A. Desmond
Renee A. Desmond
PBPhillip Brantley
Phillip Brantley
LALawrence Appel
Lawrence Appel
LSLaura Svetkey
Laura Svetkey
JAJamy D. Ard
Jamy D. Ard

1 January 2020 in Disability and Health Journal
Verified
Journal Article
Closed access
BWBrooks C. Wingo
Brooks C. Wingo
DYDershung Yang
Dershung Yang
DDDrew Davis
Drew Davis
SPSangeetha Padalabalanarayanan
Sangeetha Padalabalanarayanan
BHBetsy Hopson
Betsy Hopson
JRJIM H RIMMER
JIM H RIMMER

25 August 2017 in mHealth
Verified
Journal Article
Closed access
PDF file
ASAshley Sineath
Ashley Sineath
LLLauren Lambert
Lauren Lambert
CVCatherine Verga
Catherine Verga
MWMiranda Wagstaff
Miranda Wagstaff
BWBrooks C. Wingo
Brooks C. Wingo
Background: Technology-based lifestyle behavioral interventions (i.e., telehealth, mHealth, eHealth, and/or digital health) are becoming an alternative standard of care and possess several advantages over traditional clinical settings such as convenience, cost, and the ability to tailor plans and feedback to a participant’s individual needs. These technology-based interventions also present unique challenges to intervention fidelity due to extra elements involved in executing the intervention. Intervention fidelity monitoring is essential to ensure internal and external validity, yet the development and utilization of fidelity protocols is under-reported in the literature. The purpose of this paper is to describe the intervention fidelity protocol for the 24-START study, a behavior change intervention delivered through telephone and internet. This paper also discusses the results of a pilot audit conducted to determine the feasibility of monitoring adherence to the fidelity protocol. Methods: The 24-START fidelity protocol was developed in accordance with the five fidelity areas outlined by the NIH Behavior Change Consortium (NIH BCC) including: design of study, provider training, delivery of treatment, receipt of treatment, and enactment of treatment. The fidelity strategies provided by the NIH BCC in each area were tailored to fit the specific design of the 24-START study. Twenty-six total fidelity strategies were developed in accordance with the five areas and a corresponding fidelity monitoring plan was created. Because these strategies are only beneficial if implemented, the fidelity monitoring plan was developed to ensure the fidelity strategies are consistently implemented over the course of the intervention. Results: A pilot audit of nine participant files was conducted to test the feasibility of the fidelity protocol developed. Out of the nine participant files reviewed, 89% of scheduled phone calls between a telehealth coach and participant were successfully completed. Of the completed calls, telehealth coaches delivered the intervention as intended 85.3% of the time, and 74% of planned secondary contacts made through the internet were delivered successfully. Additionally, between treatment group dosing was found to be equal. Several weak areas in the fidelity protocol were identified for improvement. The results were satisfactory and the audit was deemed feasible for ongoing use. Conclusions: The NIH BCC provides a valuable framework for telehealth interventions to develop fidelity protocols ultimately contributing to improved internal and external validity, better translation of results, increased transparency, and increased opportunities for replication within the field. The 24-START pilot audit found the fidelity protocol efficacious and feasible while also identifying areas of weakness in need of revision. The refined protocol will continue to be utilized throughout the data collection phase. Future telehealth interventions should develop and disclose fidelity protocols to improve the overall quality and standard of telehealth interventions.

12 January 2023 in Frontiers in Neurology
Verified
Journal Article
Open access
BWBrooks C. Wingo
Brooks C. Wingo
JRJohn R. Rinker
John R. Rinker
KGKathryn Green
Kathryn Green
CPCourtney M. Peterson
Courtney M. Peterson
Introduction: Intermittent fasting (IF) has become a popular dietary pattern for adults with multiple sclerosis (MS), and initial studies in animal models and human trials indicate promising results for improving symptoms and slowing disease progression. Most studies published to date have focused on alternate day fasting or fasting mimicking diets including a 5:2 pattern, in which participants greatly restrict calorie intake on two non-consecutive days and eat regularly on other days; however, time restricted eating (TRE) may be equally effective for improving symptoms and may lead to better long term adherence due to its focus only on the time of day in which calories are consumed with no restriction on number of calories or types of food consumed.Methods: The purpose of this pilot study was to determine the feasibility and acceptability of a TRE intervention in adults with relapsing remitting MS (RRMS). Participants (n = 12) were instructed to eat all food within an 8-h window every day and fast the remaining 16 h for 8 weeks.Results: The eating pattern was determined to be feasible based on retention rates (n = 11; 92%) and acceptable based on participant feedback.Discussion: Exploratory results of changes in cognition, pain, and fatigue, indicate that further study of TRE in this population is warranted.Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT04389970; NCT04389970.